Bibliografia
PM6407V0 Glutamax advanced scheda bv
Bibliografia
1. AA. VV. Glutathione, reduced (GSH). Monograph. Alt Med Rev 2001;6(6):601-607
2. Biasibetti E, et al. E¬ ect of Glutamax® Forte, a multicomponent dietary supplement containing Silibinin-phosphatidylcholine complex, in cats with liver disease. SEJ Life Science 2018;1(1):1-12
3. Cacciatore I, et al. Prodrug approach for increasing cellular glutathione levels. Molecules 2010;15:1242-1264
4. Center SA, et al. Liver glutathione concentration in dogs and cats with natural occurring liver disease. Am J Vet Res 2002;63:1187-1197
5. Center SA. Antioxidant in liver disease: a focus on thiol supplementation. WSAVA 2006 World Congress Proceedings:423-426
6. Center SA. Standard care in chronic hepatitis. WSAVA 2006 World Congress Proceedings: 43-49
7. Di Paola R, et al. S-acetyl-glutathione attenuates carbon tetrachloride-induced liver injury by moduating oxidative imbalance and oxidation. Int J Mol Sci 2022,23:4429
8. Filburn CR, et al. Bioavailability of a silybinphosphatidylcholine complex in dogs. J Vet Pharmacol Ther. 2007;30:132-138
9. Kendall A, et al. Glutathione peroxidase activity, plasma total antioxidant activity, and urinary F2-isoprostanes as a marker of oxidative stress in anemic dogs. J Vet Intern Med 2017,31:1700-1707
10. Kidd PM, et al. A review of the bioavailability and clinical e cacy of milk thistle phytosome: a silybinphosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10(3):193-203
11. Kretszchmar M. Regulation of hepatic glutathione metabolism and its role in hepatotoxicity. Exp Toxic Pathol 1996;48:439-446
12. Indena. Siliphos technical sheet 10/2014
13. Locigno R, et al. S-acetyl-glutathione selectively induces apoptosis in human lymphoma cells thorough a GSHindependent mechanism. International Journal of Oncology 2002;20:69-75
14. Lubos E, et al. Glutathihone-peroxidase 1 in health and disease: from molecular mechanisms to therapeutic opportunity. Antioxid Redox Signal 2011;15:1957-1997
15. Martello e, et al. Antioxidant e¬ ect of a dietary supplement containing fermentative S-acetyl-glutathione and sylibin in dogs with liver disease. Vet Sci 2023;10:131
16. Scanlan N. Compromised hepatic detoxifi cation in companion animals and its correction via nutritional supplementation and modifi ed fasting. Altern Med Rev 2001;6(suppl):24-37
17. Spee B, et al. Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver disease. J Vet Intern Med 2006;20:1085-1092
18. Twedt DC. Therapeutic use of cytoprotective agents in canine and feline hepatobiliry disease. Atti 67° Congresso Nazionale SCIVAC 2010
19. Twedt DC. Hydiopatic hepatitis and chirrosis in dogs. 67° SCIVAC National Congress 2010:135-140
20. Twedt DC. The latest update on feline liver disease. NAVC Conference 2009 Proceedings:550-552
21. Twedt DC. Update on feline hepatobiliary disease. 67° SCIVAC National Congress 2010:20-126
22. Viviano KR, et al. Glutathione, cysteine and ascorbate concentration in clinically ill dogs and cats. J Vet Intern Med 2009;23:250-257
23. Webb CB et al. Assessment of oxidative stress in leukocyte and granulocyte function following oral administration of a silibininphosphatidylcholine complex in cats. Am J Vet Res 2009;70:57-62
24. Wu G, et al. Glutathione metabolism and its implication for health. J Nutr 2004;134:489-492
- Email info@candioli.it
- Telefono +39 011 3490232
- Sede S.da Antica di None, 1 - 10092 Beinasco TO
Candioli srl: P.IVA/C.F. 10358790011 / Sede: Strada Comunale di None, 1 - 10092 BEINASCO (TO) / Numero d’iscrizione REA, Sezione Ordinaria TO - 1126599 / capitale versato: 130.000 €